Translating data into an actionable R&D strategy

Dr. Lennon joined the company in October 2023 as President, CEO, and a member of the board of directors. He brings more than 20 years of experience leading global biotechnology and pharmaceutical teams, with significant expertise in oncology development and commercialization. Previously, Dr. Lennon was the Chief Executive Officer of Satellite Bio. Prior to that, he spent 15 years at Novartis, where he most recently served as President of Novartis Gene Therapies. In that role, he led the development, approval, and launch of Zolgensma®, the first systemic gene therapy for spinal muscular atrophy. He also held key commercial leadership positions in Novartis Oncology. Dr. Lennon began his career as a scientist before joining McKinsey & Company to focus on R&D strategy. He holds a PhD in Molecular Medicine from Cornell University and a BA in Biophysics from Columbia University.

Dr. Kyle Kai-How Farh has been leading the Illumina Artificial Intelligence Lab for ten years. Prior to joining Illumina, Dr. Farh spent time as an attending physician at Boston Children’s Hospital and as a Fellow at The Broad Institute. He holds an MD from Harvard Medical School, a PhD in molecular biology from Massachusetts Institute of Technology, and a BS in computer science from Rice University.

Phil Perez serves as Senior Vice President, Commercial Life Sciences. In this role, he is responsible for Tempus’ commercial strategy and structuring relationships with its biopharma partners. Phil has more than 20 years of commercial leadership experience in the fields of oncology genomics, enterprise software, and clinical research operations in both large healthcare companies and startups. Most recently, he served as Chief Commercial Officer of Verily Life Sciences, SignalPath. Prior to Verily, Phil led the commercial strategy at SignalPath, an enterprise-level research operations SaaS tool for both health systems and life sciences companies, from pre-revenue, until its acquisition by Verily. Phil holds a B.A. from the University of Michigan and an MBA from the University of North Carolina at Chapel Hill.

Dr. Martin Bontrager is a senior leader at Tempus, applying his Ph.D. and experience with real-world data to drive advancements in precision medicine. Dr. Bontrager's expertise lies in the harmonization of genomics and clinical data and developing technologies that enable rapid innovation in healthcare.